The Best Small-Cap Stocks to Buy Now
Biotech, real estate and software dominate the list of Wall Street's best small-cap stocks to buy.
The final quarter of 2025 and first quarter of the new year could be much more favorable for stockpickers looking for the best small-cap stocks to buy.
That might sound counterintuitive after the way small caps have underperformed during the current bull market. After all, small caps as an asset class have been a dud. They've struggled to keep up as mega-cap stocks pushed the broader market to record highs.
To recap: the broader S&P 500 is up more than 80% since the bull market's onset three years ago. The tech-heavy Nasdaq Composite more than doubled over the same span. Hurt partly by its price-weighted construction, the blue-chip Dow Jones Industrial Average gained just 55%.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Select Magnificent 7 stocks such as Nvidia (NVDA) and Microsoft (MSFT) have been fueling much of the market's gains. And so small caps – which tend to be more sensitive to the economic cycle, tariffs and interest rates – are lagging badly.
Indeed, the small-cap benchmark Russell 2000 Index is up just 41% over the past three years.
If there is a sliver of a silver lining to the Russell 2000's chronic underperformance, it's that small cap valuations look dirt cheap.
"The broadening of profits growth is finally extending into small caps," notes Jill Carey Hall, an equity and quant strategist at BofA Securities. "Small caps continue to trade at about a 30% historical discount to large caps, implying likelihood of outperformance over the long-term. We remain constructive on small caps for now."
And with the Federal Reserve expected to enact several cuts to the federal funds rate in the coming quarters, small caps should have at least one catalyst behind them.
Our methodology for finding the best small-caps stocks to buy
In order to find the best small-cap stocks to buy now, we started by screening the Russell 2000 for Wall Street analysts' top-rated names.
Here's how the process works: S&P Global Market Intelligence surveys analysts' stock ratings and scores them on a five-point scale, where 1.0 equals Strong Buy and 5.0 means Strong Sell.
Any score of 2.5 or lower means that analysts, on average, rate the stock a Buy. The closer the score gets to 1.0, the stronger the Buy call.
In other words, lower scores are better than higher scores.
We further limited ourselves to stocks with at least 12 Strong Buy recommendations to ensure adequate analyst coverage and sample size. Lastly, we dug into research, fundamental factors, valuation, analysts' estimates and other data to find the best stocks to buy.
Our screen of the Street's top small-cap stocks served up a list dominated by the health care sector, mostly pharmaceutical and biotechnology companies.
That's to be expected, and investors should always do their own due diligence when considering, say, a clinical-stage biotech firm, which is essentially a speculative investment.
In other cases, some of these names – a gaming stock and real estate investment trust (REIT), for instance – might just surprise you.
And with that, have a look at the table below to see Wall Street's best small-cap stocks to buy now.
Company (Ticker) | Analysts' consensus recommendation score | Subsector | Analysts' consensus recommendation |
|---|---|---|---|
Spyre Therapeutics (SYRE) | 1.14 | Biotechnology | Strong Buy |
Denali Therapeutics (DNLI) | 1.16 | Biotechnology | Strong Buy |
Waystar Holding (WAY) | 1.19 | Health Care Technology | Strong Buy |
Xenon Pharmaceuticals (XENE) | 1.21 | Biotechnology | Strong Buy |
Genius Sports (GENI) | 1.22 | Casinos & Gaming | Strong Buy |
Janux Therapeutics (JANX) | 1.22 | Biotechnology | Strong Buy |
Axsome Therapeutics (AXSM) | 1.25 | Pharmaceuticals | Strong Buy |
Wave Life Sciences (WVE) | 1.27 | Pharmaceuticals | Strong Buy |
Kymera Therapeutics (KYMR) | 1.27 | Biotechnology | Strong Buy |
Riot Platforms (RIOT) | 1.28 | Application Software | Strong Buy |
Avidity Biosciences (RNA) | 1.28 | Biotechnology | Strong Buy |
Braze (BRZE) | 1.30 | Application Software | Strong Buy |
Biohaven (BHVN) | 1.33 | Biotechnology | Strong Buy |
Guardant Health (GH) | 1.35 | Health Care Services | Strong Buy |
BridgeBio Pharma (BBIO) | 1.37 | Biotechnology | Strong Buy |
Essential Properties Realty Trust (EPRT) | 1.37 | Diversified REITs | Strong Buy |
Arcellx (ACLX) | 1.39 | Biotechnology | Strong Buy |
Privia Health Group (PRVA) | 1.40 | Health Care Services | Strong Buy |
IDEAYA Biosciences (IDYA) | 1.42 | Biotechnology | Strong Buy |
NetSTREIT (NTST) | 1.50 | Retail REITs | Strong Buy |
Related content
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Dan Burrows is Kiplinger's senior investing writer, having joined the publication full time in 2016.
A long-time financial journalist, Dan is a veteran of MarketWatch, CBS MoneyWatch, SmartMoney, InvestorPlace, DailyFinance and other tier 1 national publications. He has written for The Wall Street Journal, Bloomberg and Consumer Reports and his stories have appeared in the New York Daily News, the San Jose Mercury News and Investor's Business Daily, among many other outlets. As a senior writer at AOL's DailyFinance, Dan reported market news from the floor of the New York Stock Exchange.
Once upon a time – before his days as a financial reporter and assistant financial editor at legendary fashion trade paper Women's Wear Daily – Dan worked for Spy magazine, scribbled away at Time Inc. and contributed to Maxim magazine back when lad mags were a thing. He's also written for Esquire magazine's Dubious Achievements Awards.
In his current role at Kiplinger, Dan writes about markets and macroeconomics.
Dan holds a bachelor's degree from Oberlin College and a master's degree from Columbia University.
Disclosure: Dan does not trade individual stocks or securities. He is eternally long the U.S equity market, primarily through tax-advantaged accounts.
-
We inherited $250K: should we buy a second home or save for college?He wants a vacation home, but she wants a 529 plan for the kids. Who's right? The experts weigh in.
-
The $300,000 Social Security Decision You Could Get WrongDeciding when to claim Social Security is a complex, high-stakes decision that shouldn't be based on fear or simple break-even math.
-
4 Ways Washington Could Put Your Retirement at RiskLegislative changes, such as shifting tax brackets or altering retirement account rules, could affect your nest egg, so it'd be prudent to prepare. Here's how.
-
I'm a Financial Adviser: This Is the $300,000 Social Security Decision Many People Get WrongDeciding when to claim Social Security is a complex, high-stakes decision that shouldn't be based on fear or simple break-even math.
-
4 Ways Washington Could Put Your Retirement at Risk (and How to Prepare)Legislative changes, such as shifting tax brackets or altering retirement account rules, could affect your nest egg, so it'd be prudent to prepare. Here's how.
-
2026's Tax Trifecta: The Rural OZ Bonus and Your Month-by-Month Execution CalendarReal estate investors can triple their tax step-up with rural opportunity zones this year. This month-by-month action plan will ensure you meet the deadline.
-
Is Your Retirement Plan Built for 2026 — or Stuck in 2006?It's time to move away from the 4% rule and the 60/40 portfolio to an adaptable, tax-diversified strategy focused on reliable income and longevity.
-
Filed for Social Security Too Soon? 2 Ways to Get a Do-OverIf you've claimed Social Security too soon, two SSA rules allow a do-over. But be warned: Using them clumsily can lead to surprise repayments or lost benefits.
-
Have You Aligned Your Tax Strategy With These 5 OBBBA Changes?Individuals and businesses should work closely with their financial advisers to refine tax strategies this season in light of these five OBBBA changes.
-
Stocks Close Down as Gold, Silver Spiral: Stock Market TodayA "long-overdue correction" temporarily halted a massive rally in gold and silver, while the Dow took a hit from negative reactions to blue-chip earnings.
-
The New Fed Chair Was Announced: What You Need to KnowPresident Donald Trump announced Kevin Warsh as his selection for the next chair of the Federal Reserve, who will replace Jerome Powell.